Next-Generation Sequencing Data Analysis Industry Overview

The global next-generation sequencing data analysis market size was valued at USD 561.6 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 15.02% from 2021 to 2028.

Next-generation sequencing (NGS) has effectively helped in studying epigenomic as well as genomic patterns associated with various biological processes. However, issues pertaining to storage, management, and accessing information are expected to provide the market with potential R&D opportunities, consequently fueling the growth of the market. Research communities that use high-throughput sequencers demand Laboratory Information Management Systems (LIMSs) for handling and archiving sequencing information. Cloud-based platforms offer favourable solutions for computationally intensive tasks during the analysis of NGS data. Therefore, it has become a quick and easy approach for the acquisition of computational resources to conduct NGS data analysis at a large scale.

The development of cloud-based bioinformatics platforms and services for large-scale NGS data analysis is expected to drive the market at a fast pace. BaseSpace, Bina, DNAnexus, LifeScope, GeneSifter and SevenBridges are some of the commercially available cloud-based NGS tools readily adopted by end-users to analyze sequencing information. The incorporation of NGS protocols has been specifically used for oncology precision medicine, especially for lung and breast cancers. Companies are also focused on developing low-cost genome sequencing solutions to enhance their businesses. For instance, in October 2021, Phase Genomics announced to launch a cost-effective platform for genome analysis.

Gather more insights about the market drivers, restrains and growth of the Global Next-Generation Sequencing Data Analysis Market

Similarly, various stakeholders in the industry are looking for companies that offer low-cost solutions. For instance, Gencoveraised USD 10 million to meet the demand for interpretable and accessible whole-genome sequencing. The company manages the cost by integrating low-pass whole-genome sequencing with a proprietary software-as-a-service computation.

The spontaneous spread of COVID-19 led to the increased emphasis on genome surveillance. Moreover, enhanced capabilities of genome surveillance can support the development of intelligent systems to track virus mutations and variants associated with respiratory conditions. In June 2021, the European Centre for Disease Prevention and Control announced the launch of EpiPulse, a European surveillance portal, for infectious diseases to gather, analyze and share sequencing data associated with infectious diseases.

Furthermore, the companies are engaged in the deployment of such surveillance platforms, which can provide a robust platform for sequencing and analysis of viruses. For instance, in March 2021, Applied DNA Sciences, Inc. announced the launch of the Linea Genomic Surveillance Mutation Panel for COVID-19 to consolidate the process associated with SARS-CoV-2 variant tracking and detection. Rising awareness and adoption of such genome surveillance platforms can play a powerful role in handling future health emergencies. In addition, the growth of such platforms is expected to create a lucrative growth opportunity for next-generation sequencing data analysis platforms in the coming years.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• Synthetic Biology Market: The global synthetic biology market size was valued at USD 10,285.3 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 19.7% from 2022 to 2030. The increasing scope of synthetic biology applications for multiplexed diagnostics & cellular recording, as well as therapeutic genome editing, is anticipated to surge its demand during the study period.

• Cell Culture Media Market: The global cell culture media market size was valued at USD 3,616.8 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 12.1% from 2022 to 2030. Cell culture media is generally a gel or liquid including compounds required to regulate and support the growth of cells or microorganisms used in the manufacturing of biopharmaceuticals.

Next-Generation Sequencing Data Analysis Market Segmentation

Grand View Research has segmented the global next-generation sequencing data analysis market on the basis of product, workflow, mode, read length, end-use, and region:

Next-generation Sequencing Data Analysis Product Outlook (Revenue, USD Million, 2017 - 2028)

• Services

• NGS Commercial Software

Next-generation Sequencing Data Analysis Workflow Outlook (Revenue, USD Million, 2017 - 2028)

• Primary

• Secondary

• Tertiary

Next-generation Sequencing Data Analysis Mode Outlook (Revenue, USD Million, 2017 - 2028)

• In-house

• Outsourced

Next-generation Sequencing Data Analysis Read Length Outlook (Revenue, USD Million, 2017 - 2028)

• Short Read

• Long Read

• Very Long Read

Next-generation Sequencing Data Analysis End-use Outlook (Revenue, USD Million, 2017 - 2028)

• Academic Research

• Clinical Research

• Hospitals & Clinics

• Pharma& Biotech Entities

• Other Users

Next-generation Sequencing Data Analysis Regional Outlook (Revenue, USD Million, 2017 - 2028)

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East Africa (MEA)

Key Companies profiled:

Some prominent players in the Global Next-Generation Sequencing Data Analysis Market include

• Thermo Fisher Scientific, Inc.

• QIAGEN

• Illumina, Inc.

• F. Hoffmann-La Roche Ltd.

• Agilent Technologies, Inc.

• Bio-Rad Laboratories, Inc.

• PierianDx

• PrecigenBioinformatics Germany GmbH

• Partek Incorporated

• Eurofins Scientific

• Pacific Biosciences of California, Inc.

• DNASTAR, Inc.

• Congenica Ltd.

• Fabric Genomics, Inc.

• Genuity Science

• DNAnexus Inc.

• SciGenom Labs Pvt. Ltd.

• Golden Helix, Inc.

• Verily Life Science

Order a free sample PDF of the Next-Generation Sequencing Data Analysis Market Intelligence Study, published by Grand View Research.